Davis Polk advised Gilead, and Latham & Watkins advised the underwriters. Gilead Sciences, Inc. (Nasdaq: GILD) announced the pricing of senior unsecured notes in an aggregate...
Gilead’s $2 Billion Senior Unsecured Notes Offering
Korro Bio and Frequency Therapeutics’ Merger Agreement
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
Ironwood Pharmaceuticals’ $1 Billion Acquisition of VectivBio Holding
Advestra and Latham & Watkins advise Ironwood. Homburger AG serves as legal and tax advisor to VectivBio on the transaction. Goodwin advises Centerview Partners. VectivBio Holding...
Natus’ Acquisition of Micromed Holding SAS
Latham & Watkins LLP represented ArchiMed and Natus in the transaction. Natus Medical Incorporated (Natus), a leading provider of medical device solutions, has announced the closing...
Cordis’ Acquisition of MedAlliance
Latham & Watkins represented MedAlliance in the transaction. Swiss-based medical technology company MedAlliance announced it has entered into an agreement with Cordis for an acquisition which includes...
Nordic Capital’s Investment Into Equashield
Latham & Watkins LLP represented Nordic Capital in the transaction. Nordic Capital, a leading private equity investor, and Equashield have announced that Nordic Capital has joined Equashield’s...
MeiraGTx’s Growth Financing Agreement with Perceptive Advisors
Latham & Watkins represented MeiraGTx in the transaction. MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, announced a financing agreement with affiliates...
Amgen’s $3.7 Billion Acquisition of ChemoCentryx
Wachtell, Lipton, Rosen & Katz represented Amgen, while Latham & Watkins represented ChemoCentryx in the transaction. Amgen and ChemoCentryx, Inc., a biopharmaceutical company focused on orally...
BC Partners’ Acquisition of Havea
Latham & Watkins advised BC Partners. Jeausserand Audouard advised Havea Group. Kirkland & Ellis advised Funds advised by BC Partners on the financing of the acquisition....
Rhythm Pharmaceuticals’ $100 Million Revenue Interest Financing Agreement With HealthCare Royalty Partners
Latham & Watkins represented Rhythm Pharmaceuticals, Inc. in the transaction, while Morgan, Lewis & Bockius acted as legal advisor to HealthCare Royalty. Rhythm Pharmaceuticals, Inc. (Nasdaq:...
Goldman Sachs Asset Management’s Acquisition of Controlling Stake in Norgine Europe
Latham & Watkins has advised Norgine Europe B.V. on the deal. Allen & Overy and White & Case have advised Goldman Sachs Asset Management Division. Norgine...
Astorg’s Acquisition of CordenPharma
Freshfields Bruckhaus Deringer has advised International Chemical Investors Group on the deal, while Walder Wyss and Latham & Watkins advised Astorg. Milbank advised the management of...